Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits

• DOI: 10.1097/fjc.0b013e318197c5e9
• Publication Date: 2009-02-16T08:16:16Z
• Authors: Verónica D'Annunzio; Martín Donato; Lukas Erni; Verónica Miksztowicz; Bruno Buchholz; Cristina Lorenzo ...; Laura Schreier; Regina Wikinski; Ricardo J Gelpi; Gabriela Berg; Nidia Basso
• Keywords: Cardioprotection; Hyperlipidemia

There is evidence that statin treatment before ischemia protects myocardium from ischemia/reperfusion injury. The objective to determine whether rosuvastatin administered during reperfusion modifies infarct size and the recovery of postischemic ventricular dysfunction in normocholesterolemic hypercholesterolemic rabbits. In addition, we also evaluated role matrix metalloproteinase type 2 (MMP)-2 activation. Langendorff-perfused rabbit hearts were subjected 30 minutes 120 reperfusion. group 2, added after beginning 3, an MMP inhibitor (doxycycline) was first Finally, repeated these groups but rabbits (groups 4, 5, 6). 16.6% ± 3.9% 1 25.6% 2.7% 4. Rosuvastatin reduced 4.5% 1.1% 6.1% 1.5% respectively (P < 0.05). significantly decreased MMP-2 activity reperfusion, doxycycline induced inhibition a reduction (4.9% 0.9%) animals (8.3% 1.6%) reduces attenuates activity. These data correlation between suggest plays important mechanisms cardioprotection afforded by rosuvastatin.